Thu, 11 Oct 2018
11:30 AM – 2:15 PMAdd to Calendar
Bristol-Myers Squibb will open its new research facility in Cambridge later this year. With a fully integrated drug discovery and translational medicine organization, the site will focus on novel targets and pathways for tumors that are refractory to current Immuno-Oncology therapies, and implement our discovery platforms across all of our therapeutic areas of focus (oncology, cardiovascular disease, immunoscience, and fibrosis). This panel explores perspectives on the future of oncology therapy, and highlights some of the oncology related goals for BMS overall, and for the new Cambridge site. The panelists will also discuss the value of being in a vibrant ecosystem. With sites in Redwood City, CA, Lawrenceville, NJ, and soon in Cambridge, MA, the panel will explore how these respective sites, and the ecosystems in which they are in, position BMS to leverage biological insights, as well as innovative approaches and technologies, to tackle some of the toughest scientific problems in oncology drug research. The panelists will also offer their perspectives on what they love about their work within Bristol-Myers Squibb, what it takes to be a leader in the field, and the types of skills and backgrounds they are looking for as they seek to build an Oncology Discovery organization in Cambridge. Join us for this exciting conversation with Bristol-Myers Squibb’s oncology research leadership!
Moderated by Bruce Car, Head, Translational Medicine Science and Operations
Emma Lees, Head of Oncology Biology, Cambridge & Small Molecule IO
Nils Lonberg, Head, Oncology Discovery Biology
Mike Quigley, Head, Oncology Discovery Biology, Redwood City
11:30 AM | Registration Opens, Networking and Lunch
12:00 PM | Panel Discussion
1:00 PM | Q&A, Networking
2:15 PM | Program Close
The event is complimentary, but pre-registration is required, as seats are limited.
Contact the organizers